Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.52 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16180469 | 1.00 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11ULK1 | |
| SCHEMBL2540933 | 0.92 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2540930 | 0.92 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3047076 | 0.89 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3047225 | 0.89 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2540321 | 0.89 | MAPK14 (0.62) | MAPK14ULK1 | |
| SCHEMBL3065073 | 0.88 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3057977 | 0.87 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13086495 | 0.87 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3068319 | 0.86 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | claimed |
| EP-2220044-A1 | P38 MAP KINASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2010-08-25 | — | — | EP | claimed |
| WO-2009060160-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-14 | — | — | WO | claimed |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | disclosed |
| EP-2220044-A1 | P38 MAP KINASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009060160-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009060160-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK12 | MAPK14 13/4885MAPK13 5/4885MAPK12 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.